A detailed history of E Fund Management Co., Ltd. transactions in Arcellx, Inc. stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 5,986 shares of ACLX stock, worth $324,022. This represents 0.03% of its overall portfolio holdings.

Number of Shares
5,986
Previous 6,012 0.43%
Holding current value
$324,022
Previous $333,000 24.92%
% of portfolio
0.03%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$51.85 - $73.49 $1,348 - $1,910
-26 Reduced 0.43%
5,986 $416,000
Q4 2023

Feb 06, 2024

SELL
$31.75 - $57.99 $68,072 - $124,330
-2,144 Reduced 26.29%
6,012 $333,000
Q3 2023

Nov 13, 2023

BUY
$31.51 - $37.4 $12,824 - $15,221
407 Added 5.25%
8,156 $293,000
Q2 2023

Aug 11, 2023

SELL
$27.49 - $46.9 $7,779 - $13,272
-283 Reduced 3.52%
7,749 $245,000
Q1 2023

May 11, 2023

BUY
$26.92 - $33.94 $216,221 - $272,606
8,032 New
8,032 $247,000

Others Institutions Holding ACLX

About Arcellx, Inc.


  • Ticker ACLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,819,200
  • Market Cap $2.37B
  • Description
  • Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...
More about ACLX
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.